Saroglitazar, a PPAR-&#x3B1;/&#x3B3; Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double-Blind Phase 2 Trial

Hepatology

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation

Liver Transpl

Younossi ZM

doi: 10.1002/lt.25003.

Further Publications

Perioperative Omega-3 fatty Acids Fails to Confer Protection in Liver Surgery. Results of a multicentric, double-blind, randomized controlled trial

J Hepatol.

Linecker M, Botea F, Raptis DA, Nicolaescu D, Limani P, Alikhanov R, Kim P, Wirsching A, Kron P, Schneider MA, Tschuor C, Kambakamba P, Oberkofler C, De Oliveira ML, Bonvini J, Efanov M, Graf R, Petrowsky H, Khatkov I, Clavien PA, Popescu I

doi: 10.1016/j.jhep.2019.10.004.

Gastroesophageal Reflux Disease (GERD)

Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate-antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease

Eur J Gastroenterol Hepatol.

Wilkinson J, Wade A, Thomas SJ, Jenner B, Hodgkinson V, Coyle C

doi: 10.1097/MEG.

Hepatology

Longitudinal Correlations Between MRE, MRI-PDFF, and Liver Histology in Patients with Nonalcoholic Steatohepatitis: Analysis of Data from a Phase 2 Trial of Selonsertib

J Hepatol.

Jayakumar S, Middleton MS, Lawitz EJ, Mantry PS, Caldwell SH, Arnold H, Diehl AM, Ghalib R, Elkhashab M, Abdelmalek MF, Kowdley KV, Djedjos CS, Xu R, Han L, Subramanian GM, Myers RP, Goodman ZD, Afdhal NH, Charlton MR, Sirlin CB, Loomba R

doi: 10.1016/j.jhep.2018.09.024.

Hepatology

Synbiotic Alters Fecal Microbiomes, but not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Non-alcoholic Fatty Liver Disease

Gastroenterology.

Scorletti E, Afolabi PR, Miles EA, Smith DE, Almehmadi A, Alshathry A, Childs CE, Del Fabbro S, Beavis J, Moyses HE, Clough GF, Sethi JK, Patel J, Wright M, Breen DJ, Peebles C, Darekar A, Aspinall R, Fowell AJ, Dowman JK, Nobili V, Targher G, Delzenne NM, Bindels LB, Calder PC, Byrne CD

doi: 10.1053/j.gastro.2020.01.031.

Hepatitis

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Lancet.

Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, Alkhouri N, Bansal MB, Baum S, Neuschwander-Tetri BA, Taub R, Moussa SE

doi: 10.1016/S0140-6736(19)32517-6.

Hepatology

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study

J Hepatol.

Harrison SA, Alkhouri N, Davison BA, Sanyal A, Edwards C, Colca JR, Lee BH, Loomba R, Cusi K, Kolterman O, Cotter G, Dittrich HC

doi: 10.1016/j.jhep.2019.10.023.

RECOMMENDED

Celiac Disease

Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study

Lancet Gastroenterol Hepatol.

Cellier C, Bouma G, van Gils T, Khater S, Malamut G, Crespo L, Collin P, Green PHR, Crowe SE, Tsuji W, Butz E, Cerf-Bensussan N, Macintyre E, Parnes JR, Leon F, Hermine O, Mulder CJ, RCD-II Study Group Investigators.

doi: 10.1016/

Hepatology

Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial

Lancet Gastroenterol Hepatol.

Pose E, Napoleone L, Amin A, Campion D, Jimenez C, Piano S, Roux O, Uschner FE, de Wit K, Zaccherini G, Alessandria C, Angeli P, Bernardi M, Beuers U, Caraceni P, Durand F, Mookerjee RP, Trebicka J, Vargas V, Andrade RJ, Carol M, Pich J, Ferrero J, Domenech G, Llopis M, Torres F, Kamath PS, Abraldes JG, Solà E, Ginès P

doi: 10.1016/S2468-1253(19)30320-6.

Related content

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation

Perioperative Omega-3 fatty Acids Fails to Confer Protection in Liver Surgery. Results of a multicentric, double-blind, randomized controlled trial

Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate-antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease

Longitudinal Correlations Between MRE, MRI-PDFF, and Liver Histology in Patients with Nonalcoholic Steatohepatitis: Analysis of Data from a Phase 2 Trial of Selonsertib

Synbiotic Alters Fecal Microbiomes, but not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Non-alcoholic Fatty Liver Disease

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study

Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study

Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial